|
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) |
|
Scinai Immunotherapeutics Ltd
SCNI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Scinai Immunotherapeutics Ltd 's sales fell
in IV. Quarter 2023 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -1.86 %
• More on SCNI's Growth
|
|
Scinai Immunotherapeutics Ltd realized a net loss in trailing twelve months.
Scinai Immunotherapeutics Ltd realized cash reduction of $ -0.01 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.59.
• More on SCNI's Valuation
|
|
|
|
|
Scinai Immunotherapeutics Ltd realized net loss in trailing twelve months.
Scinai Immunotherapeutics Ltd realized cash outflow of $ -0.01per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.59.
• More on SCNI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com